ATE447949T1 - Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen - Google Patents

Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen

Info

Publication number
ATE447949T1
ATE447949T1 AT00917712T AT00917712T ATE447949T1 AT E447949 T1 ATE447949 T1 AT E447949T1 AT 00917712 T AT00917712 T AT 00917712T AT 00917712 T AT00917712 T AT 00917712T AT E447949 T1 ATE447949 T1 AT E447949T1
Authority
AT
Austria
Prior art keywords
sup
present
vacuolar
atpase
type
Prior art date
Application number
AT00917712T
Other languages
English (en)
Inventor
Michael Boyd
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE447949T1 publication Critical patent/ATE447949T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00917712T 1999-03-05 2000-03-03 Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen ATE447949T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12295399P 1999-03-05 1999-03-05
US16956499P 1999-12-08 1999-12-08
PCT/US2000/005582 WO2000051589A2 (en) 1999-03-05 2000-03-03 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE447949T1 true ATE447949T1 (de) 2009-11-15

Family

ID=26821050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917712T ATE447949T1 (de) 1999-03-05 2000-03-03 Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen

Country Status (9)

Country Link
US (2) US7381744B1 (de)
EP (1) EP1158976B1 (de)
JP (1) JP4807903B2 (de)
AT (1) ATE447949T1 (de)
AU (1) AU776397B2 (de)
CA (1) CA2366765C (de)
DE (1) DE60043293D1 (de)
ES (1) ES2338858T3 (de)
WO (1) WO2000051589A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381744B1 (en) 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
AU8083401A (en) 2000-07-24 2002-02-05 Us Health Biologically active macrolides, compositions, and uses thereof
EP1944307A3 (de) 2000-08-04 2008-07-30 Board of Regents, The University of Texas System Synthetische Salicylihalamide, Apicularene und Derivate davon
US6734209B2 (en) 2001-08-03 2004-05-11 Board Of Regents The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
AU2001278152C1 (en) 2000-08-04 2009-02-05 Board Of Regents, The University Of Texas System Synthetic salicylihalamides, apicularens and derivatives thereof
GB0102562D0 (en) 2001-02-01 2001-03-21 Unilever Plc Cosmetic products for the reduction of sweat acidity
EP1450874A2 (de) * 2001-11-29 2004-09-01 Kathy Rzeszutek Kontrolliert resorbierbare knochenimplantate
US7205334B2 (en) 2002-07-24 2007-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
LU91725B1 (en) 2010-09-02 2012-03-05 Ct De Rech Public De La Sante Novel uses of V-ATPASE inhibitors
KR101973906B1 (ko) * 2018-08-22 2019-04-29 성균관대학교산학협력단 V-atp6voc의 발현 또는 활성 억제제를 유효성분으로 포함하는, 식도암 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324720A (en) * 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
US20020042079A1 (en) * 1994-02-01 2002-04-11 Sanford M. Simon Methods and agents for measuring and controlling multidrug resistance
DE69824855T2 (de) 1997-07-25 2005-08-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Macrozyklische laktone, zusammensetzungen und verfahren zur verwendung
AUPP003197A0 (en) * 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US7381744B1 (en) * 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds

Also Published As

Publication number Publication date
CA2366765A1 (en) 2000-09-08
US7381744B1 (en) 2008-06-03
US20080275108A1 (en) 2008-11-06
WO2000051589A2 (en) 2000-09-08
WO2000051589A3 (en) 2001-07-12
JP2002538109A (ja) 2002-11-12
EP1158976B1 (de) 2009-11-11
JP4807903B2 (ja) 2011-11-02
AU776397B2 (en) 2004-09-09
EP1158976A2 (de) 2001-12-05
DE60043293D1 (de) 2009-12-24
AU3864400A (en) 2000-09-21
ES2338858T3 (es) 2010-05-13
WO2000051589A9 (en) 2001-08-02
CA2366765C (en) 2010-06-29

Similar Documents

Publication Publication Date Title
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
MY130668A (en) Isothiazole derivatives useful as anticancer agents
MY136674A (en) Novel quinuclidine carbamate derivatives and medicinal compositions containing the same
CY1105719T1 (el) Νεα κινουκλιδινικα παραγωγα και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
DK34793A (da) Vandoploeseligt, farmaceutisk acceptabelt salt af et monoacylderivat af rapamycin, fremgangsmaade til dets fremstilling og injicerbart, farmaceutisk praeparat indeholdende det
ATE398627T1 (de) C-2-modifizierte erythromycinderivate
ATE447949T1 (de) Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen
EA200000792A2 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
NO20001871L (no) Nye 3,6-hemiacetaler fra klassen 9a-azalider
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
DE60123827D1 (en) 1-methylcarbapenemderivate
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE69824855D1 (de) Macrozyklische laktone, zusammensetzungen und verfahren zur verwendung
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
KR950008515A (ko) 피리도[1,2,3-d,e][1,3,4] 벤족사디아진 유도체
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
IL151167A0 (en) Pyrrolopyridazine derivatives and pharmaceutical compositions containing the same
ATE186537T1 (de) Antibakterielle penem-ester derivate
MXPA05008190A (es) Derivado de oligosacarido.
EA200100344A2 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
GB0114699D0 (en) Organic compounds
KR890003758A (ko) 피롤로[2,1-a]이소피롤린 유도체, 그들의 제조방법, 그들을 함유하는 조성물 및 그들의 이용

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties